The webinar will feature a presentation by Key Opinion Leader (KOL) Ali Mostajelean M.D. (UCSF Benioff Children’s Hospital Oakland) who will discuss the current treatment landscape and unmet medical need in treating patients with seizures in TSC (Tuberous Sclerosis Complex). Dr. Mostajelean will both be available to answer questions following the formal presentations.

Noema’s management team will also give an update on their lead product NOE-101, an mGluR5 inhibitor, which is Phase 2b-ready for two indications: persistent seizures in Tuberous Sclerosis Complex (TSC) and severe pain in Trigeminal Neuralgia (TN). NOE-101 mGluR5 NAM, is a highly selective, potent, and cell penetrant negative allosteric modulator of mGlu5 receptors for the treatment of seizures associated with tuberous sclerosis complex (TSC) and for the management of pain associated with Trigeminal Neuralgia (TN).